Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts.

Bhagat TD, Von Ahrens D, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel B, Kwak C, Choudhary GS, Gordon-Mitchell S, Aluri S, Bhattacharyya S, Sahu S, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Guerrero PA, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D, Maitra A, Verma A.

Elife. 2019 Oct 30;8. pii: e50663. doi: 10.7554/eLife.50663. [Epub ahead of print]

2.

A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.

Hu ZI, Bendell JC, Bullock A, LoConte NK, Hatoum H, Ritch P, Hool H, Leach JW, Sanchez J, Sohal DPS, Strickler J, Patel R, Wang-Gillam A, Firdaus I, Yu KH, Kapoun AM, Holmgren E, Zhou L, Dupont J, Picozzi V, Sahai V, O'Reilly EM.

Cancer Med. 2019 Sep;8(11):5148-5157. doi: 10.1002/cam4.2425. Epub 2019 Jul 26.

3.

Multi-omic molecular comparison of primary versus metastatic pancreatic tumours.

Brar G, Blais EM, Joseph Bender R, Brody JR, Sohal D, Madhavan S, Picozzi VJ, Hendifar AE, Chung VM, Halverson D, Mikhail S, Matrisian LM, Rahib L, Petricoin E, Pishvaian MJ.

Br J Cancer. 2019 Jul;121(3):264-270. doi: 10.1038/s41416-019-0507-5. Epub 2019 Jul 11.

PMID:
31292535
4.

Molecular testing in metastatic colorectal adenocarcinoma cytology cell pellets.

McHugh KE, Dermawan JK, Cheng YW, Cruise M, Sohal DPS, Reynolds JP.

Diagn Cytopathol. 2019 Nov;47(11):1132-1137. doi: 10.1002/dc.24275. Epub 2019 Jul 9.

PMID:
31290252
5.

Guidelines Insights: Hepatobiliary Cancers, Version 2.2019.

Benson AB, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Anaya DA, Anders R, Are C, Brown D, Chang DT, Cloyd J, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Hammond LJ, Darlow SD.

J Natl Compr Canc Netw. 2019 Apr 1;17(4):302-310. doi: 10.6004/jnccn.2019.0019.

PMID:
30959462
6.

Epidemiology, Tumor Characteristics, and Survival in Patients With Primary Pancreatic Lymphoma: A Large Population-based Study Using the SEER Database.

Mukhija D, Nagpal SJS, Sohal DPS.

Am J Clin Oncol. 2019 May;42(5):454-458. doi: 10.1097/COC.0000000000000544.

PMID:
30950860
7.

Adjuvant Treatment in Potentially Curable Pancreatic Cancer: Need to Include Tumor Location in the Equation?

Mukhija D, Sohal DPS, Khorana AA.

Pancreas. 2018 Sep;47(8):e50-e52. doi: 10.1097/MPA.0000000000001125. No abstract available.

PMID:
30113430
8.

Targeted Next-Generation Sequencing in Men with Metastatic Prostate Cancer: a Pilot Study.

Barata PC, Mendiratta P, Heald B, Klek S, Grivas P, Sohal DPS, Garcia JA.

Target Oncol. 2018 Aug;13(4):495-500. doi: 10.1007/s11523-018-0576-z.

PMID:
29974386
9.

Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative.

Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, Chung V, Picozzi VJ, Sohal D, Blais EM, Mason K, Lyons EE, Matrisian LM, Brody JR, Madhavan S, Petricoin EF 3rd.

Clin Cancer Res. 2018 Oct 15;24(20):5018-5027. doi: 10.1158/1078-0432.CCR-18-0531. Epub 2018 Jun 28.

10.

Do patients with pancreatic body or tail cancer benefit from adjuvant therapy?A cohort study.

Sohal DPS, Tullio K, Khorana AA.

Surg Oncol. 2018 Jun;27(2):245-250. doi: 10.1016/j.suronc.2018.05.008. Epub 2018 May 7.

PMID:
29937178
11.

Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.

Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Ramanathan RK, Ruggiero JT, Shah MA, Urba S, Uronis HE, Lau MW, Laheru D.

J Clin Oncol. 2018 Aug 20;36(24):2545-2556. doi: 10.1200/JCO.2018.78.9636. Epub 2018 May 23.

PMID:
29791286
12.

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM.

N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.

14.

Use of 2015 Beers Criteria Medications by Older Medicare Beneficiaries.

Patel R, Zhu L, Sohal D, Lenkova E, Koshki N, Woelfel J, Ranson C, Valle-Oseguera CS, Rogan EL.

Consult Pharm. 2018 Jan 1;33(1):48-54. doi: 10.4140/TCP.n.2018.48.

PMID:
29336278
15.

Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study.

Sohal DPS, Kuderer NM, Shepherd FA, Pabinger I, Agnelli G, Liebman HA, Meyer G, Kalady MF, McCrae K, Lyman GH, Khorana AA.

JNCI Cancer Spectr. 2017 Nov 28;1(1):pkx009. doi: 10.1093/jncics/pkx009. eCollection 2017 Sep.

16.

Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients.

Dhir M, Malhotra GK, Sohal DPS, Hein NA, Smith LM, O'Reilly EM, Bahary N, Are C.

World J Surg Oncol. 2017 Oct 10;15(1):183. doi: 10.1186/s12957-017-1240-2. Review.

17.

Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance.

Barata PC, Koshkin VS, Funchain P, Sohal D, Pritchard A, Klek S, Adamowicz T, Gopalakrishnan D, Garcia J, Rini B, Grivas P.

Ann Oncol. 2017 Oct 1;28(10):2458-2463. doi: 10.1093/annonc/mdx405.

PMID:
28945843
18.

Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma.

Sohal DPS.

Chin Clin Oncol. 2017 Jun;6(3):26. doi: 10.21037/cco.2017.06.23.

19.

Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation.

Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes AM, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM, Mukherjee S, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG, Verma A.

Cancer Res. 2017 Sep 15;77(18):4846-4857. doi: 10.1158/0008-5472.CAN-17-0282. Epub 2017 Jul 6.

20.

Pancreatic Adenocarcinoma: Improving Prevention and Survivorship.

Sohal DPS, Willingham FF, Falconi M, Raphael KL, Crippa S.

Am Soc Clin Oncol Educ Book. 2017;37:301-310. doi: 10.14694/EDBK_175222. Review.

PMID:
28561672
21.

NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.

Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S.

J Natl Compr Canc Netw. 2017 May;15(5):563-573.

22.

Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary.

Sohal DP, Mangu PB, Laheru D.

J Oncol Pract. 2017 Apr;13(4):261-264. doi: 10.1200/JOP.2016.017368. Epub 2016 Oct 31. No abstract available.

PMID:
28399388
23.

Reply to A. Wang-Gillam et al.

Sohal DP, Mangu PB, Laheru D, Khorana AA.

J Clin Oncol. 2017 Feb 20;35(6):690-691. doi: 10.1200/JCO.2016.70.7463. Epub 2016 Dec 5. No abstract available.

PMID:
27918714
24.

Molecular characteristics of biliary tract cancer.

Sohal DP, Shrotriya S, Abazeed M, Cruise M, Khorana A.

Crit Rev Oncol Hematol. 2016 Nov;107:111-118. doi: 10.1016/j.critrevonc.2016.08.013. Epub 2016 Sep 13. Review.

PMID:
27823638
25.

Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes.

McNamara MJ, Adelstein DJ, Allende DS, Bodmann JW, Ives DI, Murthy SC, Raymond D, Raja S, Rodriguez CP, Sohal D, Stephans KL, Videtic GMM, Rybicki LA.

J Gastrointest Cancer. 2017 Jun;48(2):181-189. doi: 10.1007/s12029-016-9881-x.

PMID:
27734205
26.

Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O'Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D.

J Clin Oncol. 2016 Aug 10;34(23):2784-96. doi: 10.1200/JCO.2016.67.1412. Epub 2016 May 31. Review.

27.

The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen.

McNamara MJ, Rybicki LA, Sohal D, Allende DS, Videtic GM, Rodriguez CP, Stephans KL, Murthy SC, Raja S, Raymond D, Ives DI, Bodmann JW, Adelstein DJ.

J Gastrointest Oncol. 2016 Apr;7(2):196-205. doi: 10.3978/j.issn.2078-6891.2015.097.

28.

Recurrent venous thromboembolism in glioblastoma.

Edwin NC, Khoury MN, Sohal D, McCrae KR, Ahluwalia MS, Khorana AA.

Thromb Res. 2016 Jan;137:184-188. doi: 10.1016/j.thromres.2015.11.027. Epub 2015 Nov 22.

PMID:
26657302
29.

Prospective Clinical Study of Precision Oncology in Solid Tumors.

Sohal DP, Rini BI, Khorana AA, Dreicer R, Abraham J, Procop GW, Saunthararajah Y, Pennell NA, Stevenson JP, Pelley R, Estfan B, Shepard D, Funchain P, Elson P, Adelstein DJ, Bolwell BJ.

J Natl Cancer Inst. 2015 Nov 9;108(3). pii: djv332. doi: 10.1093/jnci/djv332.

PMID:
26553780
30.

Predicting early mortality in resectable pancreatic adenocarcinoma: A cohort study.

Sohal DP, Shrotriya S, Glass KT, Pelley RJ, McNamara MJ, Estfan B, Shapiro M, Wey J, Chalikonda S, Morris-Stiff G, Walsh RM, Khorana AA.

Cancer. 2015 Jun 1;121(11):1779-84. doi: 10.1002/cncr.29298. Epub 2015 Feb 11.

31.

A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, followed by surgery and postoperative concurrent cisplatin and fluorouracil chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesophageal junction.

McNamara MJ, Adelstein DJ, Bodmann JW, Greskovich JF Jr, Ives DI, Mason DP, Murthy SC, Rice TW, Saxton JP, Sohal D, Stephans K, Rodriguez CP, Videtic GM, Rybicki LA.

J Thorac Oncol. 2014 Oct;9(10):1561-7. doi: 10.1097/JTO.0000000000000312.

32.

Gefitinib in definitive management of esophageal or gastroesophageal junction cancer: a retrospective analysis of two clinical trials.

Sohal DP, Rice TW, Rybicki LA, Rodriguez CP, Videtic GM, Saxton JP, Murthy SC, Mason DP, Phillips BE, Tubbs RR, Plesec T, McNamara MJ, Ives DI, Bodmann JW, Adelstein DJ.

Dis Esophagus. 2015 Aug-Sep;28(6):547-51. doi: 10.1111/dote.12241. Epub 2014 May 21.

PMID:
24849395
33.

Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy.

Sohal DP, Walsh RM, Ramanathan RK, Khorana AA.

J Natl Cancer Inst. 2014 Mar;106(3):dju011. doi: 10.1093/jnci/dju011. Epub 2014 Feb 22. Review.

PMID:
24563516
34.

A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.

Sohal DP, Mykulowycz K, Uehara T, Teitelbaum UR, Damjanov N, Giantonio BJ, Carberry M, Wissel P, Jacobs-Small M, O'Dwyer PJ, Sepulveda A, Sun W.

Ann Oncol. 2013 Dec;24(12):3061-5. doi: 10.1093/annonc/mdt416. Epub 2013 Oct 20.

PMID:
24146220
35.

Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer.

Sohal DP, Metz JM, Sun W, Giantonio BJ, Plastaras JP, Ginsberg G, Kochman ML, Teitelbaum UR, Harlacker K, Heitjan DF, Feldman MD, Drebin JA, O'Dwyer PJ.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1485-91. doi: 10.1007/s00280-013-2147-4. Epub 2013 Mar 27.

PMID:
23532207
36.

Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.

Nischal S, Bhattacharyya S, Christopeit M, Yu Y, Zhou L, Bhagat TD, Sohal D, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski JP, Melnick AM, Greally JM, Steidl U, Moliterno A, Verma A.

Cancer Res. 2013 Feb 1;73(3):1076-85. doi: 10.1158/0008-5472.CAN-12-0735. Epub 2012 Oct 11.

37.

What is the reference cytotoxic regimen for advanced gastric cancer: standard versus optimal therapy?

Sohal DP, Sun W.

Expert Rev Anticancer Ther. 2011 Dec;11(12):1843-50. doi: 10.1586/era.11.170.

PMID:
22117152
38.

Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma.

Moghanaki D, Mick R, Furth EE, Sohal D, Salmon PM, Behbahani A, Morgans AK, Miller SM, Giantonio BJ, Whittington RW, Haller DG, Rosato EF, Plastaras JP.

JOP. 2011 Sep 9;12(5):438-44.

39.

Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q.

Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kambhampati S, Parmar S, Nischal S, Hueck C, Suzuki M, Freidman E, Pellagatti A, Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, McMahon C, Gore SD, Platanias LC, Levine R, Melnick A, Wickrema A, Greally JM, Verma A.

J Biol Chem. 2011 Jul 15;286(28):25211-23. doi: 10.1074/jbc.M111.235028. Epub 2011 Apr 30.

40.

Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis.

Alvarez H, Opalinska J, Zhou L, Sohal D, Fazzari MJ, Yu Y, Montagna C, Montgomery EA, Canto M, Dunbar KB, Wang J, Roa JC, Mo Y, Bhagat T, Ramesh KH, Cannizzaro L, Mollenhauer J, Thompson RF, Suzuki M, Meltzer SJ, Melnick A, Greally JM, Maitra A, Verma A.

PLoS Genet. 2011 Mar;7(3):e1001356. doi: 10.1371/journal.pgen.1001356. Epub 2011 Mar 31. Erratum in: PLoS Genet. 2011 May;7(5). doi: 10.1371/annotation/8dcded85-a924-40f4-a7ea-56961b87447f. Meltzer, Stephen [corrected to Meltzer, Stephen J].

41.

Hepatocellular carcinoma: prevention and therapy.

Sohal DP, Sun W.

Curr Oncol Rep. 2011 Jun;13(3):186-94. doi: 10.1007/s11912-011-0165-0.

PMID:
21409527
42.

Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.

Sun W, Sohal D, Haller DG, Mykulowycz K, Rosen M, Soulen MC, Caparro M, Teitelbaum UR, Giantonio B, O'Dwyer PJ, Shaked A, Reddy R, Olthoff K.

Cancer. 2011 Jul 15;117(14):3187-92. doi: 10.1002/cncr.25889. Epub 2011 Jan 24.

43.

Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.

Zhou L, McMahon C, Bhagat T, Alencar C, Yu Y, Fazzari M, Sohal D, Heuck C, Gundabolu K, Ng C, Mo Y, Shen W, Wickrema A, Kong G, Friedman E, Sokol L, Mantzaris I, Pellagatti A, Boultwood J, Platanias LC, Steidl U, Yan L, Yingling JM, Lahn MM, List A, Bitzer M, Verma A.

Cancer Res. 2011 Feb 1;71(3):955-63. doi: 10.1158/0008-5472.CAN-10-2933. Epub 2010 Dec 28. Erratum in: Cancer Res. 2011 Apr 1;71(7):2806. Mantzaris, Giannis [corrected to Mantzaris, Ioannis].

44.

Cerebral protection devices reduce periprocedural strokes during carotid angioplasty and stenting: a systematic review of the current literature.

Garg N, Karagiorgos N, Pisimisis GT, Sohal DP, Longo GM, Johanning JM, Lynch TG, Pipinos II.

J Endovasc Ther. 2009 Aug;16(4):412-27. doi: 10.1583/09-2713.1. Review.

PMID:
19702342
45.

Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration.

Sohal D, Yeatts A, Ye K, Pellagatti A, Zhou L, Pahanish P, Mo Y, Bhagat T, Mariadason J, Boultwood J, Melnick A, Greally J, Verma A.

PLoS One. 2008 Aug 13;3(8):e2965. doi: 10.1371/journal.pone.0002965.

46.

Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.

Zhou L, Nguyen AN, Sohal D, Ying Ma J, Pahanish P, Gundabolu K, Hayman J, Chubak A, Mo Y, Bhagat TD, Das B, Kapoun AM, Navas TA, Parmar S, Kambhampati S, Pellagatti A, Braunchweig I, Zhang Y, Wickrema A, Medicherla S, Boultwood J, Platanias LC, Higgins LS, List AF, Bitzer M, Verma A.

Blood. 2008 Oct 15;112(8):3434-43. doi: 10.1182/blood-2008-02-139824. Epub 2008 May 12.

47.

Transforming growth factor-beta signaling in normal and malignant hematopoiesis.

Isufi I, Seetharam M, Zhou L, Sohal D, Opalinska J, Pahanish P, Verma A.

J Interferon Cytokine Res. 2007 Jul;27(7):543-52. Review.

PMID:
17651015
48.

Beta-blockers are associated with reduced risk of myocardial infarction after cocaine use.

Dattilo PB, Hailpern SM, Fearon K, Sohal D, Nordin C.

Ann Emerg Med. 2008 Feb;51(2):117-25. Epub 2007 Jun 20. Erratum in: Ann Emerg Med. 2008 Jul;52(1):90.

PMID:
17583376
49.

Significance of a prenatally diagnosed del(10)(q23).

Zaslav AL, Fox JE, Jacob J, Kazi R, Allan S, Shklooskaya T, Sohal D, Kleyman SM, Verma RS.

Am J Med Genet. 2002 Jan 15;107(2):174-6.

PMID:
11807894
50.

Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein.

Sohal DS, Nghiem M, Crackower MA, Witt SA, Kimball TR, Tymitz KM, Penninger JM, Molkentin JD.

Circ Res. 2001 Jul 6;89(1):20-5.

PMID:
11440973

Supplemental Content

Support Center